

David E Kaplan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4234084/publications.pdf>

Version: 2024-02-01

143
papers

4,748
citations

101543

36
h-index

118850

62
g-index

148
all docs

148
docs citations

148
times ranked

6581
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Cancer Medicine</i> , 2023, 12, 189-199.	2.8	11
2	Comparison of infection-induced and vaccine-induced immunity against COVID-19 in patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 186-196.	7.3	11
3	Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID-19 Pandemic: A National Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 3186-3193.	4.3	4
4	Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1399-1408.	2.3	5
5	Ranitidine Use and Gastric Cancer Among Persons with <i>Helicobacter pylori</i> . <i>Digestive Diseases and Sciences</i> , 2022, 67, 1822-1830.	2.3	5
6	Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1121-e1134.	4.4	12
7	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2094-2104.	2.3	7
8	Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. <i>Transplantation</i> , 2022, 106, 72-84.	1.0	8
9	Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis. <i>Liver International</i> , 2022, 42, 384-393.	3.9	7
10	Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. <i>Gastroenterology</i> , 2022, 162, 645-647.e2.	1.3	27
11	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	7.3	26
12	External Validation of the FIPS Score for Post-TIPS Mortality in a National Veterans Affairs Cohort. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4581-4589.	2.3	9
13	Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. <i>Journal of Hepatology</i> , 2022, 76, 1100-1108.	3.7	22
14	Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4395-4402.	2.3	4
15	Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model. <i>Radiology</i> , 2022, 303, 215-225.	7.3	24
16	Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. <i>Hepatology</i> , 2022, 76, 126-138.	7.3	49
17	The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. <i>Gastroenterology</i> , 2022, 163, 257-269.e6.	1.3	22
18	Accurate long-term prediction of death for patients with cirrhosis. <i>Hepatology</i> , 2022, 76, 700-711.	7.3	5

#	ARTICLE	IF	CITATIONS
19	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	21.4	68
20	Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2148-2160.e14.	4.4	31
21	Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. <i>Hepatology</i> , 2021, 73, 219-232.	7.3	59
22	Low Rates of Retesting for Eradication of <i>Helicobacter pylori</i> Infection After Treatment in the Veterans Health Administration. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 305-313.e1.	4.4	17
23	The Predictive Role of Model for End-Stage Liver Disease Lactate and Lactate Clearance for In-Hospital Mortality Among a National Cirrhosis Cohort. <i>Liver Transplantation</i> , 2021, 27, 177-189.	2.4	21
24	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. <i>British Journal of Cancer</i> , 2021, 124, 407-413.	6.4	15
25	Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. <i>Liver Transplantation</i> , 2021, 27, 699-710.	2.4	11
26	Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2021, 27, 16-26.	2.4	20
27	Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 73, 204-218.	7.3	83
28	Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis. <i>Hepatology</i> , 2021, 74, 879-891.	7.3	36
29	Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1913-1923.	0.4	28
30	Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 1426-1436.	4.3	29
31	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. <i>Contemporary Clinical Trials</i> , 2021, 104, 106367.	1.8	13
32	Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. <i>Gastroenterology</i> , 2021, 160, 2162-2164.e3.	1.3	17
33	Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. <i>Nature Communications</i> , 2021, 12, 2579.	12.8	51
34	Development and Validation of a Model to Predict Long-Term Survival After Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 797-807.	2.4	10
35	Disentangling the obesity paradox in upper gastrointestinal cancers: Weight loss matters more than body mass index. <i>Cancer Epidemiology</i> , 2021, 72, 101912.	1.9	4
36	Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. <i>Journal of Hepatology</i> , 2021, 74, 1398-1406.	3.7	23

#	ARTICLE	IF	CITATIONS
37	External Validation of the VOCAL Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems. <i>Liver Transplantation</i> , 2021, 27, 961-970.	2.4	17
38	REPLY:. <i>Hepatology</i> , 2021, 74, 2308-2308.	7.3	0
39	Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. <i>JAMA Internal Medicine</i> , 2021, 181, 1306.	5.1	63
40	Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2402-2408.	4.4	10
41	REPLY:. <i>Hepatology</i> , 2021, 74, 2322-2323.	7.3	0
42	Identifying Patients at Highest Risk of Remaining Unvaccinated Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Large Veterans Health Administration Cohort. <i>Liver Transplantation</i> , 2021, 27, 1665-1668.	2.4	8
43	Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. <i>Cancers</i> , 2021, 13, 4849.	3.7	4
44	Variability in biopsy quality informs translational research applications in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 22763.	3.3	3
45	A Matter of TACEt: Plain Vanilla or Combination?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 934-936.	2.3	0
46	Seroprevalence of <i>Helicobacter pylori</i> Infection in a National Cohort of Veterans With Noncardia Gastric Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1235-1237.e1.	4.4	7
47	Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. <i>Hepatology</i> , 2020, 72, 230-239.	7.3	35
48	Risk Factors and Incidence of Gastric Cancer After Detection of <i>Helicobacter pylori</i> Infection: A Large Cohort Study. <i>Gastroenterology</i> , 2020, 158, 527-536.e7.	1.3	171
49	Risk prediction scores for acute on chronic liver failure development and mortality. <i>Liver International</i> , 2020, 40, 1159-1167.	3.9	22
50	Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation</i> , 2020, 104, 104-112.	1.0	14
51	The association of <i>Helicobacter pylori</i> with pancreatic cancer. <i>GastroHep</i> , 2020, 2, 157-164.	0.6	7
52	Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 2020, 173, ITC33-ITC48.	3.9	15
53	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. <i>PLoS ONE</i> , 2020, 15, e0237430.	2.5	15
54	The impact of endoscopic submucosal dissection for gastric adenocarcinomas in the United States. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2020, 22, 93-98.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study. <i>Gastroenterology</i> , 2020, 159, 1134-1136.e3.	1.3	69
56	Models for acute on chronic liver failure development and mortality in a veterans affairs cohort. <i>Hepatology International</i> , 2020, 14, 587-596.	4.2	10
57	Care quality and outcomes among US veterans with chronic hepatitis B in the hepatitis C direct-acting antiviral era. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1082-1092.	2.0	2
58	Murine hepatoblast-derived liver tumors resembling human combined hepatocellular-cholangiocarcinoma with stem cell features. <i>Cell and Bioscience</i> , 2020, 10, 38.	4.8	6
59	Oesophageal and proximal gastric adenocarcinomas are rare after detection of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 781-788.	3.7	17
60	Treatment of <i>Helicobacter pylori</i> Is Not Associated With Future <i>Clostridium difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2020, 115, 716-722.	0.4	5
61	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. <i>PLoS Genetics</i> , 2020, 16, e1008629.	3.5	101
62	T2 Hepatocellular Carcinoma Exception Policies That Prolong Waiting Time Improve the Use of Evidence-based Treatment Practices. <i>Transplantation Direct</i> , 2020, 6, e597.	1.6	7
63	Profiling the circulating mRNA transcriptome in human liver disease. <i>Oncotarget</i> , 2020, 11, 2216-2232.	1.8	16
64	Reply:. <i>Hepatology</i> , 2019, 70, 2236-2238.	7.3	4
65	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	1.3	252
66	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. <i>PLoS ONE</i> , 2019, 14, e0221614.	2.5	6
67	In-hospital mortality varies by procedure type among cirrhosis surgery admissions. <i>Liver International</i> , 2019, 39, 1394-1399.	3.9	17
68	Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. <i>Hepatology</i> , 2019, 70, 2062-2074.	7.3	35
69	Distinct phenotype and function of circulating $\gamma\delta$ 1+ and $\gamma\delta$ 2+ T-cells in acute and chronic hepatitis B. <i>PLoS Pathogens</i> , 2019, 15, e1007715.	4.7	23
70	A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: A Case Report. <i>Hepatology</i> , 2019, 70, 1477-1479.	7.3	5
71	Multidisciplinary Approach to HCC Management: How Can This Be Done?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 968-975.	2.3	16
72	Hepatocellular Cancer Induced by λ Infection. <i>Current Cancer Research</i> , 2019, , 247-259.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. <i>Gastroenterology</i> , 2019, 156, 1693-1706.e12.	1.3	98
74	Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B. <i>JAMA Internal Medicine</i> , 2019, 179, 640.	5.1	2
75	Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience. <i>Cancer Medicine</i> , 2019, 8, 1442-1446.	2.8	6
76	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. <i>Liver Transplantation</i> , 2019, 25, 1155-1164.	2.4	26
77	Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. <i>Hepatology</i> , 2019, 69, 2150-2163.	7.3	139
78	Statins and Hepatocellular Carcinoma Protection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 190-193.	0.1	1
79	Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 540-549.e4.	0.5	7
80	Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1667-1676.	2.8	16
81	Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e9757.	1.0	2
82	Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1376-1377.	2.3	4
83	Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort. <i>Journal of Viral Hepatitis</i> , 2018, 25, 187-197.	2.0	20
84	Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 106-114.e5.	4.4	38
85	Racial Disparities in Nephrology Consultation and Disease Progression among Veterans with CKD: An Observational Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2563-2573.	6.1	20
86	Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. <i>Gastroenterology</i> , 2017, 152, 1954-1964.	1.3	185
87	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. <i>Journal of Virology</i> , 2017, 91, .	3.4	4
88	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. <i>Clinical Infectious Diseases</i> , 2017, 65, 64-72.	5.8	28
89	Hepatitis C viraemia reversibly maintains subset of antigen-specific Tbet+ tissue-like memory B cells. <i>Journal of Viral Hepatitis</i> , 2017, 24, 389-396.	2.0	71
90	Persistence of exhaustion in cured hep C. <i>Blood</i> , 2017, 130, 4-4.	1.4	27

#	ARTICLE	IF	CITATIONS
91	T-bet-expressing B cells during HIV and HCV infections. <i>Cellular Immunology</i> , 2017, 321, 26-34.	3.0	54
92	Identifying Patient and Provider-specific Gaps in Care Among Patients With Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 900-906.	2.2	5
93	Prediction of Mortality in Chronic Liver Disease Using Non-hepatic Comorbidities: No SI of Relief as Yet. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1-3.	2.3	11
94	Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 864-874.	7.3	94
95	Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 282-288.	4.4	21
96	Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities. <i>Gene Expression</i> , 2017, 17, 89-98.	1.2	15
97	Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3575-3581.	1.6	76
98	Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2017, 34, S30-S39.	0.6	0
99	CD14+ regulatory dendritic cells in patients with hepatocellular carcinoma and cirrhosis. <i>Hepatology</i> , 2016, 63, 1391-1392.	7.3	4
100	Care delivery and outcomes among US veterans with hepatitis B: A national cohort study. <i>Hepatology</i> , 2016, 63, 1774-1782.	7.3	31
101	Improved Survival Among all Interferon- \pm -Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1744-1756.	2.3	3
102	Recalibrating the Child-Turcotte-Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3309-3320.	2.3	19
103	Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis. <i>Scientific Reports</i> , 2016, 6, 36862.	3.3	20
104	Does Massive Antigen Burden Allow Hepatic Viruses to Induce Regulatory T Cells and Their Tolerance and Persistence?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 259-261.	4.5	0
105	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C mono-infection, and HIV mono-infection. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 93.	1.9	12
106	Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. <i>Journal of Hepatology</i> , 2015, 63, 586-592.	3.7	121
107	Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects. <i>Cellular Immunology</i> , 2015, 295, 36-45.	3.0	6
108	Distinct Features in Natural History and Outcomes of Acute Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, e31-e40.	2.2	23

#	ARTICLE	IF	CITATIONS
109	Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2333-2341.e6.	4.4	98
110	Immunopathogenesis of Hepatitis C Virus Infection. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 735-760.	2.2	11
111	Association of Distance From a Transplant Center With Access to Waitlist Placement, Receipt of Liver Transplantation, and Survival Among US Veterans. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1234.	7.4	127
112	Liver Transplants Among US Veterans—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 437.	7.4	1
113	The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and ¹³ C isotope based metabolomics. <i>NMR in Biomedicine</i> , 2014, 27, 381-389.	2.8	35
114	Peripheral CD27 ⁺ CD21 ⁺ B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis. <i>Clinical Immunology</i> , 2014, 150, 184-191.	3.2	54
115	Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103.	2.7	6
116	Impact of oral silymarin on virus- and non-virus-specific T cell responses in chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 453-462.	2.0	16
117	Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. <i>BMC Biotechnology</i> , 2012, 12, 23.	3.3	6
118	Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. <i>Hepatology</i> , 2012, 56, 1804-1816.	7.3	67
119	Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. <i>Hepatology</i> , 2012, 55, 709-719.	7.3	83
120	Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2011, 155, 353.	3.9	53
121	Expansion of interferon-gamma-producing multifunctional CD4 ⁺ T-cells and dysfunctional CD8 ⁺ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. <i>Clinical Immunology</i> , 2011, 139, 302-313.	3.2	18
122	Short hairpin RNA-mediated silencing of bovine rotavirus NSP4 gene prevents diarrhoea in suckling mice. <i>Journal of General Virology</i> , 2011, 92, 945-951.	2.9	9
123	Homeostasis of peripheral FoxP3 ⁺ CD4 ⁺ regulatory T cells in patients with early and late stage breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 599-607.	4.2	35
124	Focal Distribution of Hepatitis C Virus RNA in Infected Livers. <i>PLoS ONE</i> , 2009, 4, e6661.	2.5	53
125	Collapse of the CD27 ⁺ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers. <i>Clinical Cancer Research</i> , 2009, 15, 4277-4287.	7.0	43
126	Rare Birds in North America: Acute Hepatitis C Cohorts. <i>Gastroenterology</i> , 2009, 136, 26-31.	1.3	53

#	ARTICLE	IF	CITATIONS
127	Do statins reduce hepatitis C RNA titers during routine clinical use?. <i>World Journal of Gastroenterology</i> , 2009, 15, 5020.	3.3	45
128	Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. <i>Hepatology</i> , 2008, 48, 70-79.	7.3	52
129	Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization. <i>Gastroenterology</i> , 2008, 134, 1927-1937.e2.	1.3	263
130	Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. <i>Journal of Hepatology</i> , 2008, 48, 903-913.	3.7	70
131	Preface. <i>Clinics in Liver Disease</i> , 2008, 12, xiii-xiv.	2.1	0
132	Global Gene Expression Profiling Unveils S100A8/A9 as Candidate Markers in H-Ras-Mediated Human Breast Epithelial Cell Invasion. <i>Molecular Cancer Research</i> , 2008, 6, 1544-1553.	3.4	87
133	Discordant Role of CD4 T-Cell Response Relative to Neutralizing Antibody and CD8 T-Cell Responses in Acute Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 654-666.	1.3	146
134	Propagation of hepatitis C virus infection: Elucidating targets for therapeutic intervention. <i>Drug Discovery Today Disease Mechanisms</i> , 2006, 3, 471-477.	0.8	0
135	Current status of vaccine therapy for hepatitis c infection. <i>Current Hepatitis Reports</i> , 2006, 5, 68-74.	0.3	0
136	T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. <i>Hepatology</i> , 2005, 41, 1365-1375.	7.3	53
137	Strain-Specific T-Cell Suppression and Protective Immunity in Patients with Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2005, 79, 6976-6983.	3.4	43
138	Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. <i>Clinics in Liver Disease</i> , 2003, 7, 683-714.	2.1	16
139	One two tandem of lamivudine and interferon might work for patients with chronic hepatitis B who failed interferon monotherapy. <i>American Journal of Gastroenterology</i> , 2002, 97, 2465-2467.	0.4	0
140	Evidence for Linkage and Association with Reading Disability, on 6p21.3-22. <i>American Journal of Human Genetics</i> , 2002, 70, 1287-1298.	6.2	112
141	REEXAMINING THE VALUE OF HEMATURIA TESTING IN PATIENTS WITH ACUTE FLANK PAIN. <i>Journal of Urology</i> , 1999, 162, 685-687.	0.4	84
142	HCV Vaccines: Coming Soon?. , 0 , 221-225.		0
143	Acute Hepatitis: Treat Immediately or Give a Chance to Spontaneously Clear?. , 0 , 25-33.		0